Sherif M Badawy1,2, Alexis A Thompson1,2, Jane L Holl1,3, Frank J Penedo4, Robert I Liem1,2. 1. a Department of Pediatrics , Feinberg School of Medicine at Northwestern University , Chicago , IL, USA. 2. b Division of Hematology , Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago , Chicago , IL, USA. 3. c Center for Healthcare Studies, Institute for Public Health and Medicine , Chicago , IL, USA. 4. d Department of Medical Social Sciences , Feinberg School of Medicine at Northwestern University , Chicago , IL, USA.
Abstract
BACKGROUND: Sickle cell disease (SCD) complications lead to poor health-related quality of life (HRQOL) and increased healthcare utilization in this population, which could be mitigated with hydroxyurea therapy; however, adherence is suboptimal. We assessed the relationship of healthcare utilization to hydroxyurea adherence and HRQOL amongst youth with SCD. METHODS: Thirty-four patients with SCD (median age 14 years, IQR 12-18) on hydroxyurea participated in this cross-sectional study and completed Morisky Adherence Scale 8-items and Patient Reported Outcomes Measurement Information System (PROMIS®) HRQOL measures. A medical chart review was conducted to assess healthcare utilization. RESULTS: Participants with more frequent hospitalizations and emergency room (ER) visits and longer length of stay (LOS) had significantly lower fetal hemoglobin (rs=-0.44; rs=-0.45; rs=-0.46, p < 0.05) and mean corpuscular volume (rs=-0.47; rs=-0.42; rs=-0.48, p < 0.05), respectively. More frequent hospitalizations and ER visits and longer LOS correlated significantly with worse fatigue (rs=0.51; rs=0.41; rs=0.53, p < 0.05), pain (rs=0.41; rs=0.38; rs=0.47, p < 0.05), physical function mobility (rs=-0.67; rs=-0.59; rs=-0.67, p < 0.05), depression (rs=0.38; rs=0.31; rs=0.42, p < 0.05), and social isolation (rs=0.76; rs=0.76; rs=-0.84, p < 0.05), respectively. CONCLUSIONS: We conclude that increased healthcare utilization in youth with SCD is associated with low adherence to hydroxyurea and worse HRQOL domain scores. It is important emphasize the clinical benefits of high adherence to hydroxyurea, particularly among youth with SCD. Future longitudinal studies are warranted to assess the directionality of these relationships, and may reveal modifiable behavioral factors associated with early changes in hydroxyurea adherence levels.
BACKGROUND:Sickle cell disease (SCD) complications lead to poor health-related quality of life (HRQOL) and increased healthcare utilization in this population, which could be mitigated with hydroxyurea therapy; however, adherence is suboptimal. We assessed the relationship of healthcare utilization to hydroxyurea adherence and HRQOL amongst youth with SCD. METHODS: Thirty-four patients with SCD (median age 14 years, IQR 12-18) on hydroxyurea participated in this cross-sectional study and completed Morisky Adherence Scale 8-items and Patient Reported Outcomes Measurement Information System (PROMIS®) HRQOL measures. A medical chart review was conducted to assess healthcare utilization. RESULTS:Participants with more frequent hospitalizations and emergency room (ER) visits and longer length of stay (LOS) had significantly lower fetal hemoglobin (rs=-0.44; rs=-0.45; rs=-0.46, p < 0.05) and mean corpuscular volume (rs=-0.47; rs=-0.42; rs=-0.48, p < 0.05), respectively. More frequent hospitalizations and ER visits and longer LOS correlated significantly with worse fatigue (rs=0.51; rs=0.41; rs=0.53, p < 0.05), pain (rs=0.41; rs=0.38; rs=0.47, p < 0.05), physical function mobility (rs=-0.67; rs=-0.59; rs=-0.67, p < 0.05), depression (rs=0.38; rs=0.31; rs=0.42, p < 0.05), and social isolation (rs=0.76; rs=0.76; rs=-0.84, p < 0.05), respectively. CONCLUSIONS: We conclude that increased healthcare utilization in youth with SCD is associated with low adherence to hydroxyurea and worse HRQOL domain scores. It is important emphasize the clinical benefits of high adherence to hydroxyurea, particularly among youth with SCD. Future longitudinal studies are warranted to assess the directionality of these relationships, and may reveal modifiable behavioral factors associated with early changes in hydroxyurea adherence levels.
Entities:
Keywords:
Sickle cell disease; adherence; healthcare utilization; hydroxyurea; quality of life
Authors: Jason R Hodges; Shannon M Phillips; Sarah Norell; Chinonyelum Nwosu; Hamda Khan; Lingzi Luo; Sherif M Badawy; Allison King; Paula Tanabe; Marsha Treadwell; Lucia Rojas Smith; Cecelia Calhoun; Jane S Hankins; Jerlym Porter Journal: Blood Adv Date: 2020-09-22
Authors: Susan E Creary; Chase Beeman; Joseph Stanek; Kathryn King; Patrick T McGann; Sarah H O'Brien; Robert I Liem; Jane Holl; Sherif M Badawy Journal: Pediatr Blood Cancer Date: 2022-04-04 Impact factor: 3.838
Authors: Claudia Di Lorenzo Oliveira; Shannon Kelly; Cesar de Almeida-Neto; Anna Barbara Carneiro-Proietti; Fabiana Chagas Camargos Piassi; Tassila Salomon; Miriam V Flor-Park; Claudia Maximo; Daniela Werneck Rodrigues; Rosimere Afonso Mota; Carolina Miranda Teixeira; Paula Loureiro; Ester Cerdeira Sabino; Brian Custer Journal: Pediatr Hematol Oncol Date: 2019-09-06 Impact factor: 1.969
Authors: Sherif M Badawy; Kaleab Z Abebe; Charlotte A Reichman; Grace Checo; Megan E Hamm; Jennifer Stinson; Chitra Lalloo; Patrick Carroll; Santosh L Saraf; Victor R Gordeuk; Payal Desai; Nirmish Shah; Darla Liles; Cassandra Trimnell; Charles R Jonassaint Journal: JMIR Res Protoc Date: 2021-05-14
Authors: Nicole M Alberts; Sherif M Badawy; Jerlym S Porter; Jane S Hankins; Jason Hodges; Jeremie H Estepp; Chinonyelum Nwosu; Hamda Khan; Matthew P Smeltzer; Ramin Homayouni; Sarah Norell; Lisa Klesges Journal: JMIR Mhealth Uhealth Date: 2020-05-08 Impact factor: 4.773
Authors: Avery A Rizio; Menaka Bhor; Xiaochen Lin; Kristen L McCausland; Michelle K White; Jincy Paulose; Savita Nandal; Rashid I Halloway; Lanetta Bronté-Hall Journal: Qual Life Res Date: 2020-01-13 Impact factor: 4.147